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Abstract Single nucleotide polymorphisms (SNPs) in the
proximity of the interleukin-28B (IL28B) gene can predict
spontaneous resolution of hepatitis C virus (HCV) infection
and response to interferon therapy. Screening for this poly-
morphism has become part of the standard criteria for the
management of HCV-infected patients, hence the need for a
rapid, cost-effective screening method. Here, we describe a
rapid PCR-based test to screen for two IL28B SNPs
(rs12979860 and rs8099917). We used this test to investi-
gate IL28B polymorphism and prevalence in a cohort of
French Canadian injection drug users who are part of a
unique population known to have a strong genetic founder
effect. This population had lower linkage disequilibrium
between the two tested SNPs as compared to other cohorts
(|d′|=0.68, r=0.59). The special genetic makeup should be
considered in the management of HCV-infected patients
within that population.
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Introduction
Hepatitis C virus (HCV) infection is a major health problem
affecting 130 million individuals worldwide with an increas-
ing rate of new infections among injection drug users (IDUs)
(Alter 2007). While approximately 25 % of HCV-exposed
individuals can clear the virus spontaneously, the majority
become persistently infected (Hoofnagle 2002). Chronic
HCV infection leads to progressive liver damage over a period
of years or decades and even liver cancer (Heathcote 2004;
Hoofnagle 2002). Several studies in humans and chimpanzees
have demonstrated that adaptive T cell responses are essential
for spontaneous viral clearance (Dustin and Rice 2007;
Shoukry et al. 2004; Walker 2010) but little is known about
host genetic factors that influence HCV resolution.
Recent genome-wide association studies (GWAS) have
identified polymorphism in or around the interleukin-28B
(IL28B) gene as an important predictor of therapeutic and
spontaneous HCV clearance (Ge et al. 2009; Suppiah et al.
2009; Thomas et al. 2009). The correlation with therapeutic
HCV clearance was validated by several groups and across
different genotypes (Mangia et al. 2010) as well as in in-
dividuals coinfected with human immunodeficiency virus
(HIV) (Rallon et al. 2010; Rauch et al. 2010). Two main
single nucleotide polymorphisms (SNPs) were identified as
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the major predictors of viral clearance, known as sustained
viral response, following interferon (IFN) therapy:
rs12979860 (3 kb upstream of IL28B) and rs8099917
(8 kb upstream of IL28B). Given that the IL28B and IL29
genes are in opposite orientation, these SNPs are upstream
of both genes. It was also demonstrated that these two SNPs
are in linkage disequilibrium. For rs12979860, the respond-
er genotype is identified as C and the nonresponder as T. For
rs8099917, the responder genotype is identified as T and the
nonresponder genotype as G. The responder genotypes were
linked to a higher expression of IL28A/B as measured by
qRT-PCR in peripheral blood mononuclear cells (PBMCs)
(Suppiah et al. 2009) and lower HCV viral load. The
nonresponder genotypes were associated with higher ex-
pression of IFN-stimulated gene signal in the liver (Ge et
al. 2009), which is considered as a predictor of nonresponse
to IFN therapy (Chen et al. 2005). The rs12979860 SNP was
also strongly associated with spontaneous viral clearance
(Rauch et al. 2010; Thomas et al. 2009; Thompson et al.
2010). The predictive value was even higher when com-
bined with plasma levels of interferon-γ-inducible protein-
10 (IP-10) in the context of response to therapy (Darling et
al. 2011) and spontaneous resolution (Beinhardt et al. 2012).
IL28B genotyping has become an important diagnostic tool
for the management of HCV-infected patients. This test will
continue to be important for new treatment regimens using
direct acting antivirals in combination with IFN (Holmes et al.
2012) and even in IFN-free regimens (Barreiro et al. 2012).
While a number of tests based on RT-PCR and direct sequenc-
ing were developed and are now available commercially, there
is a need for a rapid and inexpensive test especially in a
research or limited resources setting. The goals of this study
were as follows: first, to develop a rapid, PCR-based tech-
nique for screening of both rs12979860 and rs8099917 and,
second, to use this validated method to evaluate the preva-
lence of the different IL28B SNPs in a cohort of IDUs at high
risk of HCV infection inMontréal, QC, Canada. This cohort is
mainly composed of French Canadians, a population known
to have a strong founder effect (Roy-Gagnon et al. 2011;
Scriver 2001) which may influence the SNP distribution and
consequently clinical management of this cohort.
Patients and methods
Study population
Participants were recruited among high-risk IDUs, defined
as IDUs who reported sharing injection material or having
an HCV-positive partner in the past 6 months, participating
in the Montreal Acute Hepatitis C Cohort (HEPCO) at St-
Luc Hospital of the Centre Hospitalier de l’Université de
Montréal as previously described (Badr et al. 2008; Cox et
al. 2009; Grebely et al. 2012). Subjects who were tested
positive for hepatitis B virus or HIV were excluded from the
study to prevent confounding of the association between
IL28B genotype and HCV clearance. Additional patients
undergoing standard-of-care pegylated IFN-α and ribavirin
combination therapy were recruited from the Hepatology
Department of St-Luc Hospital, Montréal, QC, Canada. This
study was approved by the Institutional Ethics Committee
(SL05.014, SL05.025) and conducted according to the Dec-
laration of Helsinki. All participants signed an informed
consent upon enrolment and, for those included in this
study, gave a specific consent for genetic testing. A total
of 17 eligible participants (<10 %) refused genetic testing;
these were 74.5 % males, 94.1 % Caucasian, and with a
mean age of 33.6 years.
Blood sampling and testing
Immediately, 100–200 μl of EDTA blood samples was flash
frozen and used for later testing onwhole blood. Alternatively,
PBMCs were isolated on a Ficoll gradient and cryopreserved.
PBMCs were either used directly to extract genomic DNA or
to generate EBV-transformed B lymphocyte cell lines (BLCL)
as previously described (Tosato and Cohen 2007) as an alter-
native source of genomic DNA for genotyping.
Genomic DNA isolation
Genomic DNAwas extracted from 200 μl of whole blood or
5×106 PBMCs or BLCL using a Blood DNA Extraction Kit
(Feldan, Quebec City, QC, Canada) following the manufac-
turer’s protocol.
PCR amplification and IL28B genotyping by sequencing
Isolated genomic DNAwas PCR-amplified with standard Taq
polymerase (Life Technologies, Carlsbad, CA, USA) using
appropriate oligonucleotide primer pairs in a total volume of
50 μl per reaction. PCR conditions were as follows: initial
denaturation cycle at 94 °C for 2 min, 40 amplification cycles
of 94 °C for 30 s, 55.5 °C for 1 min, and 72 °C for 3 min. A
final extension step at 72 °C for 7 min was applied. The PCR-
amplified fragments were sequenced by the Sanger Sequencing
Service using Applied Biosystem’s 3730xl DNA Analyzer
technology at the McGill University and Génome Québec
Innovation Centre, Montréal, QC, Canada. The sequencing
chromatogram was read to obtain the genotype and to discri-
minate between homozygotes and heterozygotes.
IL28B screening by PCR
The isolated genomic DNA was PCR-amplified with stan-
dard Taq polymerase (Life Technologies, Carlsbad, CA, USA)
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using appropriate oligonucleotide primer pairs in a total of
25-μl reaction volume. PCR conditions in thermocycler
(Biometra, Goettingen, Germany) were as follows: initial de-
naturation at 94 °C for 2 min, followed by 35 cycles of 94 °C
for 30 s, 65 °C for 15 s, and 72 °C for 1 min for rs12979860 or
30 cycles of 94 °C for 30 s, 54.5 °C for 15 s, and 72 °C for
1 min for rs8099917. A final extension step at 72 °C for 7 min
was applied in each case. Appropriate volumes of the PCR
reactions were resolved on a 2 % agarose gel and the genotype
was determined by the presence of amplified bands of interest.
Statistical analysis
Two measures of linkage disequilibrium (r and |d′|) between
rs12979860 and rs8099917 were calculated using the PROC
ALLELE procedure implemented in SAS software (SAS
Institute, Cary, NC, USA). Haplotype frequencies were esti-
mated while accounting for Hardy–Weinberg equilibrium
using the EM algorithm and the PROC HAPLOTYPE proce-
dure implemented in SAS.
Results
Development of a rapid PCR-based screening for IL28B
SNPs
We developed a rapid PCR-based test for screening of
IL28B SNPs rs12979860 and rs8099917. Primers for
IL28B SNP screening were designed from consensus human
sequences (NCBI contig NT_011109.16) using the Primer-
BLAST tool from the NCBI (Rozen and Skaletsky 2000)
and the appropriate SNP mutations. The reverse test primers
were designed so that the last nucleotide is the targeted SNP
and the primer would therefore anneal or not depending on
the patient’s or sample genotype. Primer sequences are
listed in Table 1. Genomic DNA was extracted from fresh
or frozen whole blood, PBMCs, or BLCLs. Samples were
then amplified by PCR with primers specific for each SNP
and then resolved on an agarose gel to determine the geno-
type of each individual. Representative PCR results are
demonstrated in Fig. 1. Similar results were obtained
irrespective of the source of genomic DNA.
To validate our PCR-based new screening technique, we
first sequenced 20 selected participants for each SNP using
conventional sequencing protocols, and the results were
concordant in 19/20 (95 %) of the tested samples for
rs12979860 and 20/20 (100 %) for rs8099917. To further
validate the results, 72 participants were retested by PCR–
restriction fragment length polymorphism (PCR-RFLP) as
previously described (Suppiah et al. 2009); 67 out of 72
results were identical for rs12979860 (93 % concordance) and
71 out of 72 results were identical for rs8099917 (98 % con-
cordance). Taking sequencing as the gold standard, the validity
of our test is similar to some of the other rapid tests that were
developed recently (Nakamoto et al. 2011). The samples that
Table 1 IL28B PCR and se-
quencing primers Primer name Sequence (5′–3′) Description
rs12979860
rs12-Forward GGAAGGAGCAGTTGCGCT Forward primer for all purposes
rs12-Reverse-Seq TAGGAGAGGCGCCTGCTGGG Reverse primer for sequencing
rs12-Reverse-C GCAATTCAACCCTGGTTCG Reverse primer for testing genotype C
rs12-Reverse-T GCAATTCAACCCTGGTTCA Reverse primer for testing genotype T
rs8099917
rs80-Forward CCACTTCTGGAACAAATCGTC Forward primer for all purposes
rs80-Reverse-Seq TTAGGCCTGTGGATGAGGC Reverse primer for sequencing
rs80-Reverse-G GGTTCCAATTTGGGTGAC Reverse primer for testing genotype G
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Fig. 1 Sample results of the new rapid PCR-based technique. a Sam-
ple results for screening of rs12979860 showing a mock PCR, a
heterozygote genotype (C/T), a homozygote nonresponder (T/T), and
a homozygote responder (C/C). b Sample results for screening of
rs8099917 showing a mock PCR, a homozygote nonresponder
(G/G), a heterozygote genotype (G/T), a homozygote responder
(T/T), and another heterozygote genotype (G/T)
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were discordant between our test and the PCR-RFLP test were
retyped by sequencing. These samples were all typed as CC
and were typed as CT by our test suggesting that the test might
be less powerful in some heterozygote patients.
Distribution of IL28B SNPS in the French Canadian
population
Next, we investigated allelic distribution of IL28B SNPs in
the Montreal HEPCO cohort of IDUs at high risk of HCV
infection. Participants were classified into independent but
slightly overlapping populations based on their status at
time of recruitment into the cohort:
(A) Base population (n=183) consists of HCV-naïve indi-
viduals at high risk of infection identified as HCV RNA
negative and anti-HCVantibody negative at recruitment
with one or more risk factor for HCV infection. Assum-
ing that IL28B genotype had no effect on recruitment
and selection into this population, it was used as a base
population to determine the genetic makeup of theMon-
treal HEPCO IDU which is representative of the French
Canadian IDU population in Montreal.
In order to examine the overall prevalence of the
IL28B SNPs in individuals who have cleared HCV
either spontaneously or following treatment, two addi-
tional populations were formed:
(B) Spontaneous resolvers (n=67) consists of individuals
who resolved spontaneously a previous HCV infec-
tion, identified as HCV RNA negative and anti-HCV
antibody positive with no prior history of treatment.
This included 12 individuals from population (A) who
became acutely infected with HCV and spontaneously
cleared the virus after joining the cohort as well as 55
other long-term spontaneous resolvers who were al-
ready HCV RNA negative and anti-HCV antibody
positive at the time of recruitment.
(C) Sustained virological responders (SVRs) (n=56) con-
sist of individuals who have cleared a previous HCV
infection following treatment. This population was
identified as HCV RNA negative and anti-HCV anti-
body positive with documented IFN therapy. This
included 12 individuals from population (A) who be-
came persistently infected and underwent treatment
following recruitment into the cohort as well as 44
other long-term SVRs who had already achieved
sustained viral response at the time of recruitment.
Demographics and patient characteristics are summarized
in Table 2. All populations were predominantly Caucasian,
male, and with a comparable mean age at recruitment.
Analysis of the overall prevalence of the different
IL28B alleles and genotypes in the base population
(A) is presented in Table 3. We observed a very high
and comparable prevalence of the responder C allele of
the rs12979860 SNP (90.2 %) and of the T allele of the
rs8099917 (91.3 %). The nonresponder C/Tor T/T genotypes,
Table 2 Demographics of the different populations studied








(A) Base population 183 32.6 82.0 90.2 N/A
(B) Spontaneous resolvers 67 36.4 73.1 82.1a 5/5/2/54
(C) SVRs 56 38.2 78.6b 92.7a 25/14/4/13
N/A not applicable
a Individuals for which this information was not available were excluded from this calculation (two in population (B), one in population (C))
b Includes one transgender male to female individual, who was considered male for the study purposes
Table 3 Base popula-













Table 4 Base population combined SNP results (n=183)
rs12979860
C/C C/T T/T
rs8099917 T/T 82 32 2
G/T 10 35 6
G/G 2 4 10
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hereafter referred to as */T or nonresponder genotype of
rs12979860, were more prevalent than the G/T or G/G geno-
types, hereafter referred to as */G or nonresponder genotype
of rs8099917 (48.6 vs 36.6 %). When compared to previous
studies in similar cohorts, we observed high disparity in the
frequency of the nonresponder genotype of the two SNPs
resulting in a relatively high proportion of individuals
(30.6 %) who do not have the same genotypic status for both
SNPs (i.e., rs12979860 is C/T (heterozygote) while
rs8099917 is T/T (homozygote responder)) (Table 4 and
Fig. 2). The estimated haplotypes, accounting for Hardy–
Weinberg equilibrium of each marker in the estimation,
showed that the C-T haplotype was the most frequent
(61.1 %), followed by T-T (16.3 %), T-G (13.0 %), and C-G
(9.7%). As a result, we observed partial linkage disequilibrium
between the two SNPs with |d′|=0.68 and r=0.59. This differs
greatly from studies done in other population where |d′| is
often equal to or very close to 1, including studies done
exclusively in Caucasian populations (Lindh et al. 2011;
Rauch et al. 2010).
Favorable IL28B SNPs are more prevalent in HCV resolvers
While we observed a higher prevalence of the two responder
SNPs as compared to other cohorts, the cumulative incidence
of spontaneous viral clearance in this population (18 patients
out of 89 of population (A) who were followed during acute
HCV infection, 20.2 %) was similar to what was observed in
other cohorts (Micallef et al. 2006). Nevertheless, analysis of
the overall prevalence of these two SNPs in all spontaneous
resolvers (population (B) consisting of 67 spontaneous re-
solvers) demonstrated a higher prevalence of the rs12979860
responder genotype (58.2 vs 51.4 %) and of the rs8099917
responder genotype (76.1 vs 63.4 %) compared to base pop-
ulation (A). Similarly, analysis of the overall prevalence of the
responder SNPs in all sustained viral response patients (pop-
ulation (C) SVRs, consisting of 56 SVRs) demonstrated
higher prevalence of the responder genotype C/C of
rs12979860 in this subpopulation with (62.5 vs 51.4 %) than
in the base population (A); this difference was not as strong in



























(A) Base population 
Fig. 2 Prevalence of IL28B genotypes in the French Canadian popu-
lation compared to the US and Australian populations. Left: Prevalence
of SNPs rs12979860 and rs8099917 in our study's base population (A).
Overlaying shows portions of the population that have different allelic
status for rs8099917 and rs12979860. Right: Prevalence of these SNPs
in the populations studied in the original GWAS articles of IL28B
polymorphism and HCV showing higher prevalence of responder
genotype in the French Canadian population
Table 5 IL28B SNPs and
spontaneous resolution of HCV Population (A) Base population (B) Spontaneous resolvers (C) SVRs
Genotype frequency % frequency (n=183) % frequency (n=67) % frequency (n=56)
rs12979860
C/C 51.4 (94) 58.2 (39) 62.5 (35)
*/T 48.6 (89) 41.8 (28) 37.5 (21)
rs8099917
T/T 63.4 (116) 76.1 (51) 66.1 (37)
*/G 36.6 (67) 23.9 (16) 33.9 (19)
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Discussion
Here, we described a rapid PCR-based genetic testing tool
for screening of IL28B SNPs rs12979860 and rs8099917
that can be applied to various sample types. While other
techniques such as PCR-RFLP, RT-PCR, and direct se-
quencing exist, they are usually more time consuming and
are always more expensive than a simple PCR. This test
therefore offers an inexpensive alternative to currently used
tests while being as accurate as proven by the comparison
with direct sequencing. It would be particularly useful in a
research setting or in a cost-constrained setting, as it can be
done on a minimal volume of either fresh or frozen whole
blood or a low number of patient PBMCs.
The Montreal IDU population is unique compared to
previously studied populations in being a predominantly
French Canadian population (90.2 % of base population
answered White/Caucasian ethnicity in the recruitment
questionnaire). The more than six million French Canadians
in the province of Quebec are descendants of less than
10,000 French settlers of New France in the seventeenth
and eighteenth centuries (Scriver 2001). Genetic studies
have identified a strong founder effect in this population
(Roy-Gagnon et al. 2011; Scriver 2001). This may explain
the higher percentage of responder genotype than in other
cohorts (Fig. 2) and the unique disparity in the two responder
genotypes resulting in lower linkage disequilibrium than what
was observed in other cohorts.
Because of the small numbers in our different subgroups,
we could not accurately assess the role of the two IL28B
SNPs in spontaneous or therapeutic viral clearance. Other
covariates, such as gender or HCV genotype, could not be
assessed as the cohort was predominantly male and many
patients could not be genotyped because of limited sample
availability. Nevertheless, we observed that the spontaneous
viral clearance population was enriched in individuals with
the responder genotype. We also observed that, in our specific
population, rs12979860 is more variable (nonresponder geno-
type present in 48.6 % of population vs 36.6% for rs8099917).
As a consequence, rs12979860 might be a better predictor of
clearance following treatment in this population. This
warrants an investigation in a larger cohort where other
covariates including other genetic factors or SNPs could
be examined.
Despite the higher prevalence of the two responder SNPs
as compared to other cohorts (Fig. 2), this was not associ-
ated with a better rate of spontaneous viral clearance in
acute HCV-infected individuals of population (A), as com-
pared to results from other cohorts (20.2 vs 26 %, respec-
tively) (Micallef et al. 2006). This could be due to several
factors. First is the lower linkage disequilibrium between the
two responder SNPs or other host genetic factors like the
recently identified IFNL4 gene located upstream of the
IL28B gene (Prokunina-Olsson et al. 2013). It is also pos-
sible that the rate of clearance is influenced by the fact that
all our participants are IDUs with potential lifestyle and
socioeconomic problems. Other potential factors could be
viral load and viral evolution within that specific population
(Liu et al. 2012). Immune factors might also be involved as
demonstrated by the use of baseline IP-10 serum levels
(Beinhardt et al. 2012). It also has been suggested that
IL28B polymorphism may influence outcome of acute
HCV indirectly by modulating NK cell activity (Dring et
al. 2011; Suppiah et al. 2011). Therefore, host genetics is an
important predictor of outcome of acute HCV infection, but
its predictive value would be greatly enhanced by consider-
ing other factors such as the host immune response and viral
variation, especially in smaller study populations.
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